JP Morgan Chase’s NervGen Pharma NGEN Stock Holding History
Bought
Maintained
Sold
Other funds holding NGEN
JP Morgan Chase's NGEN Position: Q3 2026 in Review
JP Morgan Chase reduced its NervGen Pharma (NGEN) stake by 8.7% in Q3 2026, selling an estimated $2.46K and leaving 13,431 shares worth $25.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6827.
JP Morgan Chase first reported a position in NGEN in Q1 2026 and has held it in 3 quarters since. The position peaked at $78.6K in Q1 2026. 68 funds tracked by Wall St. Rank hold NGEN as of Q3 2026.
- JP Morgan Chase held 13,431 shares of NervGen Pharma worth $25.8K as of Q3 2026.
- JP Morgan Chase sold 1,283 NervGen Pharma shares in Q3 2026, an estimated $2.46K.
- NervGen Pharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #6827 holding.
- JP Morgan Chase first reported a position in NervGen Pharma in Q1 2026 and has held it in 3 quarters since.
- JP Morgan Chase's NervGen Pharma position peaked at $78.6K in Q1 2026.
- 68 funds tracked by Wall St. Rank held NervGen Pharma as of Q3 2026.
Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.